These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 26683239)

  • 41. Systems Biology Methods for Alzheimer's Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials.
    Castrillo JI; Lista S; Hampel H; Ritchie CW
    Methods Mol Biol; 2018; 1750():31-66. PubMed ID: 29512064
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Future directions in Alzheimer's disease from risk factors to prevention.
    Imtiaz B; Tolppanen AM; Kivipelto M; Soininen H
    Biochem Pharmacol; 2014 Apr; 88(4):661-70. PubMed ID: 24418410
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
    Sampson EL; Jenagaratnam L; McShane R
    Cochrane Database Syst Rev; 2012 May; 5(5):CD005380. PubMed ID: 22592705
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Primary prevention and delay of onset of AD/dementia.
    Feldman HH; Jacova C
    Can J Neurol Sci; 2007 Mar; 34 Suppl 1():S84-9. PubMed ID: 17469689
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.
    Ayutyanont N; Langbaum JB; Hendrix SB; Chen K; Fleisher AS; Friesenhahn M; Ward M; Aguirre C; Acosta-Baena N; Madrigal L; Muñoz C; Tirado V; Moreno S; Tariot PN; Lopera F; Reiman EM
    J Clin Psychiatry; 2014 Jun; 75(6):652-60. PubMed ID: 24816373
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?
    Messner DA; Rabins P; Downing AC; Irizarry M; Foster NL; Al Naber J; Dabbous O; Fillit H; Gabler S; Krakauer R; Lotz D; Payzant E; Schneider L; Tyrone J; Van Amerongen D; Wuest D
    J Prev Alzheimers Dis; 2019; 6(1):20-26. PubMed ID: 30569082
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD).
    Walter S; Clanton TB; Langford OG; Rafii MS; Shaffer EJ; Grill JD; Jimenez-Maggiora GA; Sperling RA; Cummings JL; Aisen PS
    J Prev Alzheimers Dis; 2020; 7(4):219-225. PubMed ID: 32920623
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Physical activity and prevention of Alzheimer's dementia: current evidence and feasibility of an interventional trial].
    Weih M; Abu-Omar K; Esselmann H; Gelbrich G; Lewczuk P; Rütten A; Wiltfang J; Kornhuber J
    Fortschr Neurol Psychiatr; 2009 Mar; 77(3):146-51. PubMed ID: 19283649
    [TBL] [Abstract][Full Text] [Related]  

  • 50. B-vitamins and fatty acids in the prevention and treatment of Alzheimer's disease and dementia: a systematic review.
    Dangour AD; Whitehouse PJ; Rafferty K; Mitchell SA; Smith L; Hawkesworth S; Vellas B
    J Alzheimers Dis; 2010; 22(1):205-24. PubMed ID: 20847412
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiac risk factors and potential treatments in Alzheimer's disease.
    Bergmann C; Sano M
    Neurol Res; 2006 Sep; 28(6):595-604. PubMed ID: 16945210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alzheimer's disease and vascular dementia: one potentially preventable and modifiable disease? Part II: Management, prevention and future perspective.
    Davey DA
    Neurodegener Dis Manag; 2014; 4(3):261-70. PubMed ID: 25095820
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of epilepsy for people with Alzheimer's disease.
    Liu J; Wang LN
    Cochrane Database Syst Rev; 2021 May; 5(5):CD011922. PubMed ID: 33973646
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevention of Alzheimer's disease and dementia. Major findings from the Kungsholmen Project.
    Fratiglioni L; Winblad B; von Strauss E
    Physiol Behav; 2007 Sep; 92(1-2):98-104. PubMed ID: 17588621
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies.
    Frisoni GB; Molinuevo JL; Altomare D; Carrera E; Barkhof F; Berkhof J; Delrieu J; Dubois B; Kivipelto M; Nordberg A; Schott JM; van der Flier WM; Vellas B; Jessen F; Scheltens P; Ritchie C
    Alzheimers Dement; 2020 Oct; 16(10):1457-1468. PubMed ID: 32815289
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease.
    Lopez Lopez C; Tariot PN; Caputo A; Langbaum JB; Liu F; Riviere ME; Langlois C; Rouzade-Dominguez ML; Zalesak M; Hendrix S; Thomas RG; Viglietta V; Lenz R; Ryan JM; Graf A; Reiman EM
    Alzheimers Dement (N Y); 2019; 5():216-227. PubMed ID: 31211217
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selegiline for Alzheimer's disease.
    Birks J; Flicker L
    Cochrane Database Syst Rev; 2003; (1):CD000442. PubMed ID: 12535396
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nimodipine for primary degenerative, mixed and vascular dementia.
    López-Arrieta ; Birks J
    Cochrane Database Syst Rev; 2001; (1):CD000147. PubMed ID: 11279679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia.
    McGuinness B; Todd S; Passmore P; Bullock R
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004034. PubMed ID: 19821318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.